Whereas the pharmaceutical and biotechnology industries have traditionally revolved around chemical entities and biological molecules, they have already begun to transition to a very different model for product development. New products are not only being developed in traditional research laboratories, but they are also being developed in computer databases and processors. Pharmaceutical and biotechnology companies are partnering with high tech computer and data companies to employ new data-driven methods to identify potential targets, therapeutic agents, and vulnerable patient populations. This panel will explain the confluence of seemingly opposing technologies, and explore the expanding opportunities for cooperation, partnership, and licensing.

Pricing: $49